BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37323266)

  • 1. Conversion therapy for massive hepatocellular carcinoma: A case report and literature review.
    Zhou Z; Xu X; Sun M; Liu Y; Liu Q; Chen C; Yin Y
    Clin Case Rep; 2023 Jun; 11(6):e7533. PubMed ID: 37323266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic Artery Infusion Chemotherapy Sequential Hepatic Artery Embolization Combined with Operation in the Treatment of Recurrent Massive Hepatocellular Carcinoma Achieved Pathological Complete Response: A Case Report.
    Chen J; Liao X; Wu Y; Ou S; Qin W; Yang C; Tan Y; Lao Q; Peng M; Peng T; Ye X
    Pharmgenomics Pers Med; 2023; 16():949-958. PubMed ID: 37933333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma.
    Liu BJ; Gao S; Zhu X; Guo JH; Zhang X; Chen H; Wang XD; Yang RJ
    World J Gastrointest Oncol; 2020 Jun; 12(6):663-676. PubMed ID: 32699581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.
    Pan Y; Mei J; Chen J; Zhang D; Wang J; Wang X; Yi M; Zhou Z; Zhang Y; Chen M; Guo R; Xu L
    Ann Surg Oncol; 2022 Mar; 29(3):2016-2029. PubMed ID: 34637058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: Massive Hepatocellular Carcinoma Complete Surgical Resection After Portal Vein Embolization and Multimodality Therapy.
    Lin Q; Chen D; Li K; Fan X; Cai Q; Lin W; Qin C; He T
    Front Radiol; 2022; 2():858963. PubMed ID: 37492679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study.
    Wang L; Wang H; Cui Y; Liu M; Jin K; Xu D; Wang K; Xing B
    Front Oncol; 2023; 13():1115109. PubMed ID: 36874115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy.
    Xie QY; Liu HY; Guo ZY; Wu YP; He GL; Cai L; Pan MX; Fu SJ
    Front Mol Biosci; 2021; 8():810251. PubMed ID: 35187075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
    Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review.
    Zhu S; Yu Y; Yang M; Liu X; Lai M; Zhong J; Zhao X; Lu L; Liu Y
    Expert Rev Anticancer Ther; 2024 Apr; ():1-12. PubMed ID: 38651280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study.
    Guo W; Gao J; Zhuang W; Wu Z; Li B; Chen S
    JGH Open; 2020 Jun; 4(3):477-483. PubMed ID: 32514457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports.
    Tomonari T; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Okamoto K; Miyamoto H; Muguruma N; Saito Y; Imura S; Bando Y; Shimada M; Takayama T
    Medicine (Baltimore); 2020 Oct; 99(42):e22782. PubMed ID: 33080748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report.
    Chen Z; Chen Z; Fan W; Zou Y; Zhang Y; Shi N; Jin H
    World J Surg Oncol; 2023 Jan; 21(1):29. PubMed ID: 36721173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody.
    Xu B; Zhu XD; Shen YH; Zhu JJ; Liu J; Li ML; Tang PW; Zhou J; Fan J; Sun HC; Huang C
    Front Immunol; 2022; 13():1016736. PubMed ID: 36505445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
    J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report.
    Liu Z; Fu Z; Li G; Lin D
    Onco Targets Ther; 2020; 13():10267-10273. PubMed ID: 33116607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations.
    Zhu XD; Huang C; Shen YH; Ji Y; Ge NL; Qu XD; Chen L; Shi WK; Li ML; Zhu JJ; Tan CJ; Tang ZY; Zhou J; Fan J; Sun HC
    Liver Cancer; 2021 Jul; 10(4):320-329. PubMed ID: 34414120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced hepatocellular carcinoma with hepatic vein tumor thrombosis and renal dysfunction after hepatic arterial infusion chemotherapy effectively treated by liver resection with active veno-venous bypass: report of a case.
    Itoh A; Sadamori H; Yabushita K; Monden K; Tatsukawa M; Hioki M; Hyodo T; Omonishi K; Ueki T; Ohno S; Sakaguchi K; Takakura N
    BMC Cancer; 2016 Sep; 16(1):705. PubMed ID: 27586890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma.
    Chen K; Luo CP; Ge DX; Wang KL; Luo Q; Li YZ; You XM; Xiang BD; Li LQ; Ma L; Zhong JH
    Front Oncol; 2022; 12():946693. PubMed ID: 36276151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.
    Lee BH; Lee DS; Cho CW; Yun SS
    World J Surg Oncol; 2019 Aug; 17(1):143. PubMed ID: 31416447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk.
    Kosaka Y; Kawaoka T; Aikata H; Suehiro Y; Yamaoka K; Ando Y; Namba M; Takeuchi Y; Fujii Y; Uchikawa S; Kodama K; Oya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Kimura T; Nagata Y; Chayama K
    Clin J Gastroenterol; 2020 Oct; 13(5):839-843. PubMed ID: 31974811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.